NEXGEL Reports Second Quarter 2025 Financial Results
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL) reported robust financial results for the second quarter of 2025, ending June 30, 2025. The company achieved a remarkable revenue of $2.88 million, marking a significant increase of 100.3% compared to $1.44 million in the same quarter of 2024. The growth was bolstered by heightened consumer demand for its branded products and fruitful new contracts in manufacturing.
The gross profit for the quarter was recorded at $1.26 million, leading to a gross profit margin of 43.6%, more than doubling from 20.3% a year prior. Although the company continued to report net losses — a loss of $0.67 million compared to $0.89 million a year earlier — it signified improvements in performance as it heads towards a stronger second half of the year.
NEXGEL's EBITDA for the quarter stood at ($0.53) million, displaying a slight improvement in operating loss from ($0.58) million in Q1 2025. The adjusted EBITDA also improved to ($0.42) million from ($0.50) million from the preceding quarter. Operational expenses rose to $1.89 million, reflecting increased investment in compensation, advertising, and professional services.
CEO Adam Levy noted that the company is optimistic about the second half of 2025, anticipating significant growth with new product launches and customer onboarding. Recently, NEXGEL expanded its partnership with STADA, securing a $1 million advance to propel marketing and product efforts. The company maintains its revenue guidance for 2025 of $13 million and aims for positive EBITDA by year-end.
With a strong cash position supported by new financing activities, NEXGEL remains committed to leveraging its strategic growth initiatives in the healthcare and consumer products markets.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) reported impressive Q2 2025 financial results, with revenue reaching $2.88 million—a 100.3% year-over-year increase. This growth was primarily driven by strong consumer demand and new contract manufacturing agreements. The gross profit margin surged to 43.6%, significantly up from 20.3% in Q2 2024, indicating improved cost management and operational efficiency.
Despite these positive indicators, the company recorded a net loss of $0.67 million, slightly reduced from $0.89 million in the prior year, signaling ongoing challenges in achieving profitability. Importantly, NEXGEL has reiterated its 2025 revenue target of $13 million and aims to achieve positive EBITDA by year-end, underlining management's confidence in future growth potential.
The strategic advancement of partnerships, such as the recent $1 million non-dilutive capital injection from STADA, showcases NEXGEL's solidifying market position and its capability to support product launches and marketing initiatives—important drivers for the anticipated increase in sales. Additionally, the company successfully closed on financings totaling $1.05 million, which should help sustain its growth momentum.
From an investment perspective, potential investors should consider NEXGEL's trajectory of revenue growth, expanding product line, and the successful management of operational costs. The ability to achieve positive EBITDA remains a critical focal point; if management's guidance materializes, it could enhance investor confidence and bolster stock performance.
However, investors should note the inherent volatility and risk associated with NEXGEL's operating model, particularly given the current net losses. A cautious approach, closely monitoring upcoming product launches and market responses, is advisable. Long-term investors may find value in NEXGEL's promising growth strategy, but short-term fluctuations should be anticipated as the company continues its growth journey.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year
Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024
Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year
LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the period ending June 30, 2025.
Second Quarter 2025 Financial Highlights:
| ? | Net Revenue was $2.88 million, compared to $1.44 million in Q2 2024 and $2.81 million in Q1 2025. | |
| ? | Gross Profit was $1.26 million, compared to $0.29 million in Q2 2024 and $1.19 million in Q1 2025. | |
| ? | Gross Profit Margin was 43.6%, compared to 20.3% in Q2 2024 and 42.4% in Q1 2025. | |
| ? | Net loss attributable to NEXGEL stockholders was $0.67 million, compared to $0.89 million in Q2 2024 and $0.71 million in Q1 2025. | |
| ? | EBITDA 1 , a non-GAAP financial measure, was ($0.53) million, compared to EBITDA of ($0.58) million in Q1 2025 and an EBITDA of ($0.73) million in Q4 2024. | |
| ? | Adjusted EBITDA 1 , a non-GAAP financial measure, was ($0.42) million, compared to Adjusted EBITDA of ($0.50) million in Q1 2025 and Adjusted EBITDA of ($0.62) million in Q4 2024. |
“For the second quarter of 2025 we reported strong revenue and gross margin with a steady decline of our Adjusted EBITDA loss as we head into seasonally a strong second half of the year. The year-over-year growth was led by growth in consumer demand for our branded products and new agreements in contract manufacturing. In both parts of our business, we expect significant growth opportunities in the second half of 2025 as new consumer product launches for our brands come online and we onboard new contract manufacturing customers in our robust pipeline,” said Adam Levy, Chief Executive Officer of NEXGEL. “Subsequent to the quarter, we expanded our partnership with STADA, which includes a $1 million advance in non-dilutive capital to support product launches and marketing efforts. Additionally we closed on financings for $1.05 million in gross proceeds, which is sufficient to support our upcoming growth initiatives. We remain confident in our previously issued guidance for 2025 of $13 million in revenue and to achieve positive EBITDA during the year.”
Second Quarter 2025 Financial Results
For the second quarter of 2025, revenue totaled $2.88 million, an increase of 100.3%, as compared to $1.44 million for the second quarter of 2024. The increase in overall revenues was primarily due to sales growth in both contract manufacturing and branded products.
Cost of revenues totaled $1.63 million for the second quarter of 2025, as compared to $1.15 million for the second quarter of 2024. The increase in cost of revenues is primarily aligned with sales of branded consumer products, as Silly George was acquired midway through the comparable 2024 time period.
Gross profit totaled $1.26 million for the second quarter of 2025, as compared to a gross profit of $0.29 million for the second quarter of 2024. Gross profit margin for the second quarter of 2025 was 43.6%, as compared to 20.3% for the second quarter of 2024. The increase of $0.97 million in gross profit on a year-over-year basis was primarily due to both an increase in contract manufacturing and consumer branded products given the acquisition of Silly George midway through the comparable 2024 time period.
Selling, general and administrative expenses totaled $1.89 million for the second quarter of 2025, as compared to $1.27 million for the second quarter of 2024. The increase year-over-year was attributable to increases in compensation and benefits, share-based compensation, advertising, professional and consulting fees, other fees, and investor and shareholder services, which was partly offset by a decrease in depreciation and amortization.
EBITDA 1 , a non-GAAP financial measure, totaled ($0.53) million for the second quarter of 2025 as compared to ($0.76) million for the second quarter of 2024.
Adjusted EBITDA 1 , a non-GAAP financial measure, totaled ($0.42) million for the second quarter of 2025 as compared to ($0.79) million for the second quarter 2024.
Net loss attributable to NEXGEL stockholders for the second quarter of 2025 was?$0.67 million, as compared to a net loss of $0.89 million for the second quarter of 2024.
As of June 30, 2025, the Company had a cash balance of approximately $0.73 million. Subsequent to the quarter, the Company expanded its partnership with STADA, which includes a $1 million advance in non-dilutive capital from STADA to support product launches and marketing efforts. Additionally, the Company closed on financings for $1.05 million in gross proceeds.
As of August 12, 2025, NEXGEL had 8,067,580 shares of common stock outstanding.
1. EBITDA and Adjusted EBITDA are a non-GAAP measures described in the section titled Non-GAAP Financial Measures” below and reconciled to the most directly comparable GAAP measures at the end of this release.
Second Quarter 2025 Financial Results Conference Call
Date: August 12, 2025
Time: 4:30 p.m. ET
Live Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through August 26, 2025, by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11159686. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal ® , Hexagels ® , Turfguard ® , Kenkoderm ® and Silly George ® . Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Non-GAAP Financial Measures
Certain Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company’s core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company’s operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our expectation for significant growth opportunities in the second half of 2025 as new consumer product launches for our brands come online and we onboard new contract manufacturing customers in our robust pipeline and our continued expectation to generate at least $13 million in revenue for 2025 and achieve positive EBITDA during the year. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/ .
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com
NEXGEL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2025 AND DECEMBER 31, 2024
(Unaudited)
(in thousands, except share and per share data)
| June 30, 2025 | December 31, 2024 | |||||||
| ASSETS: | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 725 | $ | 1,807 | ||||
| Accounts receivable, net | 753 | 933 | ||||||
| Inventory, net | 1,821 | 1,751 | ||||||
| Prepaid expenses and other current assets | 863 | 623 | ||||||
| Total current assets | 4,162 | 5,114 | ||||||
| Goodwill | 1,128 | 1,128 | ||||||
| Intangibles, net | 744 | 807 | ||||||
| Property and equipment, net | 2,070 | 2,211 | ||||||
| Operating lease - right of use asset | 1,512 | 1,628 | ||||||
| Other assets | 95 | 95 | ||||||
| Total assets | $ | 9,711 | $ | 10,983 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 826 | $ | 761 | ||||
| Accounts payable - related party | 447 | 531 | ||||||
| Accrued expenses and other current liabilities | 534 | 310 | ||||||
| Deferred revenue | 180 | 179 | ||||||
| Current portion of note payable | 99 | 97 | ||||||
| Warrant liability | 14 | 118 | ||||||
| Contingent consideration liability | - | 178 | ||||||
| Financing lease liability, current portion | 62 | 59 | ||||||
| Operating lease liabilities, current portion | 234 | 237 | ||||||
| Total current liabilities | 2,396 | 2,470 | ||||||
| Operating lease liabilities, net of current portion | 1,446 | 1,538 | ||||||
| Financing lease liability, net of current portion | 275 | 307 | ||||||
| Notes payable, net of current portion | 539 | 588 | ||||||
| Total liabilities | 4,656 | 4,903 | ||||||
| Commitments and Contingencies (Note 17) | - | - | ||||||
| Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding | - | - | ||||||
| Common stock, par value $0.001 per share, 25,000,000 shares authorized; 7,654,537 and 7,638,497 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 8 | 8 | ||||||
| Additional paid-in capital | 24,036 | 23,743 | ||||||
| Accumulated deficit | (19,373 | ) | (17,996 | ) | ||||
| Total NexGel stockholders’ equity | 4,671 | 5,755 | ||||||
| Non-controlling interest in joint venture | 384 | 325 | ||||||
| Total stockholders’ equity | 5,055 | 6,080 | ||||||
| Total liabilities and stockholders’ equity | $ | 9,711 | $ | 10,983 |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
(Unaudited)
(in thousands, except share and per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues, net | $ | 2,884 | $ | 1,440 | $ | 5,690 | $ | 2,706 | ||||||||
| Cost of revenues | 1,626 | 1,147 | 3,244 | 2,187 | ||||||||||||
| Gross profit | 1,258 | 293 | 2,446 | 519 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | - | 76 | 1 | 78 | ||||||||||||
| Selling, general and administrative | 1,894 | 1,271 | 3,858 | 2,366 | ||||||||||||
| Total operating expenses | 1,894 | 1,347 | 3,859 | 2,444 | ||||||||||||
| Loss from operations | (636 | ) | (1,054 | ) | (1,413 | ) | (1,925 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense, net | (21 | ) | (29 | ) | (42 | ) | (44 | ) | ||||||||
| Loss on sale of assets | - | (4 | ) | - | (4 | ) | ||||||||||
| Other expense | (37 | ) | - | (76 | ) | - | ||||||||||
| Other income | 41 | 6 | 109 | 6 | ||||||||||||
| Gain on investments | - | 23 | - | 57 | ||||||||||||
| Changes in fair value of warrant liability | 13 | 79 | 104 | 26 | ||||||||||||
| Total other income (expense), net | (4 | ) | 75 | 95 | 41 | |||||||||||
| Loss before income taxes | (640 | ) | (979 | ) | (1,318 | ) | (1,884 | ) | ||||||||
| Income tax expense | - | - | - | - | ||||||||||||
| Net loss | (640 | ) | (979 | ) | (1,318 | ) | (1,884 | ) | ||||||||
| Less: Income (loss) attributable to non-controlling interest in joint venture | (25 | ) | 94 | (59 | ) | 146 | ||||||||||
| Net loss attributable to NexGel stockholders | $ | (665 | ) | $ | (885 | ) | $ | (1,377 | ) | $ | (1,738 | ) | ||||
| Net loss per common share - basic | $ | (0.09 | ) | $ | (0.14 | ) | $ | (0.18 | ) | $ | (0.28 | ) | ||||
| Net loss per common share - diluted | $ | (0.09 | ) | $ | (0.14 | ) | $ | (0.18 | ) | $ | (0.28 | ) | ||||
| Weighted average shares used in computing net loss per common share - basic | 7,654,348 | 6,254,659 | 7,649,878 | 6,118,212 | ||||||||||||
| Weighted average shares used in computing net loss per common share – diluted | 7,654,348 | 6,254,659 | 7,649,878 | 6,118,212 |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024
(Unaudited)
(in thousands)
| Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (1,377 | ) | $ | (1,738 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Income (loss) attributable to non-controlling interest in joint venture | 59 | (146 | ) | |||||
| Depreciation and amortization | 225 | 144 | ||||||
| Net changes in operating lease assets and liabilities | 21 | 22 | ||||||
| Share-based compensation and restricted stock vesting | 293 | 118 | ||||||
| Gain on investment in marketable securities | — | (57 | ) | |||||
| Changes in fair value of warrant liability and warrant modification expense | (104 | ) | (26 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | 180 | 28 | ||||||
| Inventory | (70 | ) | (127 | ) | ||||
| Prepaid expenses and other assets | (240 | ) | (68 | ) | ||||
| Accounts payable | 65 | 117 | ||||||
| Accounts payable – related party | (84 | ) | (105 | ) | ||||
| Accrued expenses and other current liabilities | 224 | (113 | ) | |||||
| Deferred revenue | 1 | 159 | ||||||
| Net Cash Used in Operating Activities | (807 | ) | (1,792 | ) | ||||
| Investing Activities | ||||||||
| Proceeds from sales of marketable securities | — | 57 | ||||||
| Capital expenditures | (20 | ) | (361 | ) | ||||
| Net cash paid for asset acquisition | — | (400 | ) | |||||
| Net Cash Used in Investing Activities | (20 | ) | (704 | ) | ||||
| Financing Activities | ||||||||
| Proceeds from equity offering, net of expenses | — | 946 | ||||||
| Investment by joint venture partner | — | 37 | ||||||
| Payment of contingent consideration liability | (178 | ) | (69 | ) | ||||
| Principal payment on financing lease liability | (29 | ) | (22 | ) | ||||
| Principal payments of notes payable | (48 | ) | (27 | ) | ||||
| Net Cash Provided by (Used in) Financing Activities | (255 | ) | 865 | |||||
| Net Decrease in Cash | (1,082 | ) | (1,631 | ) | ||||
| Cash?–?Beginning of period | 1,807 | 2,700 | ||||||
| Cash?–?End of period | $ | 725 | $ | 1,069 | ||||
| Supplemental Disclosure of Cash Flows Information | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | 18 | $ | 27 | ||||
| Taxes | $ | — | $ | — | ||||
| Supplemental Non-cash Investing and Financing activities | ||||||||
| Shares issued in conjunction with asset acquisition | $ | — | $ | 200 | ||||
| Property and equipment financed under notes payable | $ | — | $ | 165 | ||||
| Property and equipment financed under financing leases | $ | — | $ | 416 |
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
(in thousands, except per share amounts)
CALCULATION OF EBITDA & ADJUSTED EBITDA
| Three Months Ended March 31, | Three Months Ended June 30, | |||||||||||
| 2025 | 2025 | 2024 | ||||||||||
| Net (loss) income: | $ | (678 | ) | $ | (640 | ) | $ | (979 | ) | |||
| Less: Loss (income) attributable to non-controlling interest in joint venture | (34 | ) | (25 | ) | 94 | |||||||
| Net loss attributable to NexGel stockholders | (712 | ) | (665 | ) | (885 | ) | ||||||
| Adjustments: | ||||||||||||
| Depreciation and amortization | 114 | 111 | 92 | |||||||||
| Interest expense, net | 21 | 21 | 29 | |||||||||
| Income tax expense | - | - | - | |||||||||
| EBITDA | (577 | ) | (533 | ) | (764 | ) | ||||||
| Change in warrant liability(1) | (91 | ) | (13 | ) | (79 | ) | ||||||
| Share-based compensation expense(2) | 166 | 127 | 55 | |||||||||
| Adjusted EBITDA: | $ | (502 | ) | $ | (419 | ) | $ | (788 | ) |
| Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Net (loss) income: | $ | (1,318 | ) | $ | (1,884 | ) | ||
| Less: Loss (income) attributable to non-controlling interest in joint venture | (59 | ) | 146 | |||||
| Net loss attributable to NexGel stockholders | (1,377 | ) | (1,738 | ) | ||||
| Adjustments: | ||||||||
| Depreciation and amortization | 225 | 144 | ||||||
| Interest expense, net | 42 | 44 | ||||||
| Income tax expense | - | - | ||||||
| EBITDA | (1,110 | ) | (1,550 | ) | ||||
| Change in warrant liability (1) | (104 | ) | (26 | ) | ||||
| Share-based compensation expense ( 2) | 293 | 118 | ||||||
| Adjusted EBITDA: | $ | (921 | ) | $ | (1,458 | ) |
| (1 | ) | This adjustment gives effect to non-cash warrant liability changes incurred during the periods. | |
| (2 | ) | The adjustments represent share-based compensation expense related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of non-cash stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects. |
FAQ**
How does the recent financial performance of NEXGEL, Inc., including the 100.3% increase in revenue year-over-year, impact investor sentiment concerning the NexGel Inc Warrant NXGLW?
Given the company's reiterated guidance for $13 million revenue in 2025, what are the likely implications for the value of the NexGel Inc Warrant NXGLW if this guidance is achieved?
With gross profit margins improving to 43.6% in Q2 2025, how might this affect the trading dynamics of the NexGel Inc Warrant NXGLW in the coming quarters?
Considering the financial losses reported, including a net loss of $0.67 million in Q2 2025, how should investors evaluate the risk-reward profile of the NexGel Inc Warrant NXGLW?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:
